BioMedNewsBreaks

FridayOct 22, 2021 9:44 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Global Small Cap Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Global Small Cap Conference. The event is slated to take place from Oct. 27-28, 2021, with Vivos’ presentation scheduled to begin at 12:15 p.m. ET on Wednesday, Oct. 27. Interested investors should visit https://ibn.fm/jz90E to register for a free spectator pass. A replay will be available for view following…

Continue Reading

ThursdayOct 21, 2021 9:51 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Clinical Hold on Planned Eating Disorder Phase 2a Study

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, reported that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on its upcoming Phase 2a study for eating disorders. According to the announcement, the FDA did not cite a reason for the hold but would provide additional information regarding the hold in the next month. Although the study is now on hold, the company noted that it still expects to move forward with plans to file an IND for its Phase 2a study in fibromyalgia; that…

Continue Reading

WednesdayOct 20, 2021 3:29 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Showcasing Innovations in OSA Treatment at 2021 Annual Breathing Wellness Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, has announced the commencement of the 3rd-annual Breathing Wellness Conference presented by The Vivos Institute. The event is taking place at Caesars Palace in Las Vegas, Nevada, from Oct. 20-23, 2021, where dentists and medical doctors from around the world will hear from the industry’s top experts on OSA about its impact on chronic conditions such as heart disease, chronic fatigue and dementia. Attendees will also have the opportunity learn how innovations…

Continue Reading

TuesdayOct 19, 2021 2:21 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid to Bring Airway and Sleep, Oral Health, Orthodontic Therapy Together in Comprehensive Solution

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, have announced a new collaboration. Under the partnership, the companies will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network. Additionally, under the agreement, Vivos and Candid will join forces to explore new research and development opportunities for device development and other alliances related to…

Continue Reading

MondayOct 18, 2021 11:57 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid Collaborate to Deliver Comprehensive Treatment Solution

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, today announced a new collaboration. The partnership will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network. “By teaming with Candid, we are aiming to provide patients with access not only to our highly effective Vivos System, but also simultaneous access to CandidPro’s novel orthodontic…

Continue Reading

FridayOct 15, 2021 11:37 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Focusing on What It Does Best

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently released its financial results for the twelve months ended May 31, reporting on its first full year of operations since incorporation in March 2020. “The company initially began the year developing a nootropic line of functional mushrooms and supplements, in line with the rising consumer use of cognitive enhancement nootropics to improve brain function. With the company’s renewed focus on its digital technology and research development activities, MINDCURE announced in August that it had discontinued the development of its nootropics line of…

Continue Reading

FridayOct 15, 2021 11:28 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Enabling Hospitals with Efficient EEG Testing Solution

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is making it possible for all hospitals to perform EEG tests efficiently. Its neurotech ecosystem gives neurologists the resources they need to automate tedious tasks and focus their energy on the patient while simultaneously broadening their range of impact. With the unavailability of EEGs in emergency response vehicles and a majority of the hospitals in the U.S. (around 5,900 of the approximately 6,090 total hospitals lack the necessary extensive EEG tech coverage), BRSF has created a solution that includes the clinical-grade NeuroCap(TM) and the NeuroEEG(TM). “By…

Continue Reading

FridayOct 15, 2021 11:07 am

BioMedNewsBreaks – Why Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’

Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Founded in 2011, the company set out to create a single platform technology to measure blood markers at the surface of the skin. Since then, it has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and wellbeing. “Its flagship product, sugarBEAT(R), is a wearable, non-invasive, and flexible continuous glucose monitor (‘CGM’) designed to help people with diabetes and pre-diabetes manage their glucose levels. Insulin users…

Continue Reading

WednesdayOct 13, 2021 10:37 am

BioMedNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Guides Demonstrate Significant Reduction of Pediatric Tooth Decay in Peer-Reviewed Study

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced results from a peer-reviewed, published study by an independent dentist. The findings demonstrate a significant reduction of tooth decay in pediatric patients after undergoing treatment using the company’s FDA Class 1 registered Vivos Guide, a flexible, BPA-free base polymer intraoral device. A preformed positioner intended to prevent a child’s teeth from shifting and may seal the lips to convert mouth breathing to nose breathing, the Vivos Guide is worn…

Continue Reading

TuesdayOct 12, 2021 11:29 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at KSCA Psychedelics Virtual Investor Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the KCSA Psychedelics Virtual Investor Conference at 3:00 p.m. ET on Oct. 14, 2021. The event is slated to take place virtually on Oct. 13-14, 2021. Tryp’s Chief Financial Officer Luke Hayes will provide a live overview of the company's activities and elaborate on how Tryp is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications. Interested parties should visit https://ibn.fm/1Y2RX to…

Continue Reading